Skip to content

Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors

Cancer | Psychological

There is a need to develop, evaluate, and disseminate self-directed, easily accessible, safe, affordable, and effective psychosocial interventions to people living with cancer (PLWC) post-treatment. Smartphone app-based health interventions are an innovative way to deliver psychosocial cancer-care. The Mindfulness-Based Cancer Survivorship (MBCS) Journey app is a mobile app format of the Mindfulness-based Cancer Recovery program. In the SEAMLESS Study, the investigators aim to evaluate the MBCS Journey app (a 4 week mind-body intervention) in cancer survivors post-treatment. This is a randomized wait-list controlled trial. Participants will either be assigned into the immediate group (will receive intervention immediately after enrollment) or the waitlist group (wait for 3 months before receiving the intervention).

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Adult ≥ 18 years
* Diagnosed with any type of cancer (stages I-IV)
* Completed primary treatment (i.e. surgery, chemotherapy, radiation therapy) at least 2 weeks (14days) prior. Note: ongoing maintenance therapy, hormone-blocking therapies, intermittent bone-modifying agents, herceptin and targeted therapy with trastuzumab are not exclusionary.
* Have access to a smartphone with data or wifi connection.
* Willing to devote 20-30 mins of time to mindfulness practices daily during the 4-week intervention period.
* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form (e-consent) prior to enrollment in the study to document their willingness to participate.
* Participant is able (i.e. sufficiently fluent) and willing to complete the MBCS Journey and outcome measures in either English or French. The baseline assessment must be completed within required timelines, prior to randomization.
* In accordance with CCTG policy, protocol intervention is intended to begin within 7 calendar days of patient randomization.
* Participants must be willing to complete the MBCS Journey and complete the follow-up questionnaires

Exclusion Criteria:

* Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or cognitive impairment (score of ≤ 6; as assessed by the centre CRA using the three questions from the Brief Screen for Cognitive Impairment (BSCI)) listed in the screening CRF, which could interfere with completing the intervention and/or the questionnaires (i.e. inability to read or write)
* Suffering from untreated Major Depressive Disorder or other psychiatric disorders that would interfere with participation. (Note: Participants will be referred for treatment and invited to call back once in remission).
* Previous experience practicing in-person or app-based mindfulness once a week or more within the last year.

Study Location

BCCA - Kelowna
BCCA - Kelowna
Kelowna, British Columbia
Canada

Contact Study Team

Primary Contact

Saroj Niraula

250 979-6650
Western Manitoba Cancer Centre
Western Manitoba Cancer Centre
Brandon, Manitoba
Canada

Contact Study Team

Arthur J.E. Child Comprehensive Cancer Centre
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta
Canada

Contact Study Team

BCCA - Victoria
BCCA - Victoria
Victoria, British Columbia
Canada

Contact Study Team

Primary Contact

Caroline Holloway

250 519-5609
BCCA - Prince George
BCCA - Prince George
Prince George, British Columbia
Canada

Contact Study Team

Primary Contact

Irina Sainchuk

250 645-7300
Horizon Health Network
Horizon Health Network
Fredericton, New Brunswick
Canada

Contact Study Team

Primary Contact

M. Saleem Raza

506 447-4095
Kingston Health Sciences Centre
Kingston Health Sciences Centre
Kingston, Ontario
Canada

Contact Study Team

Primary Contact

April Swoboda

613 544-2361
Study Sponsored By
Canadian Cancer Trials Group
Participants Required
More Information
Study ID: NCT05470010